Research programme: Janus kinase inhibitors - BioCryst

Drug Profile

Research programme: Janus kinase inhibitors - BioCryst

Latest Information Update: 11 Dec 2012

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Dec 2012 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 05 Nov 2010 BioCryst receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
  • 03 Nov 2010 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top